Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. It also owns a 100% interest in the Frances Creek barium sulfate (barite) project, which is a rare grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.


TSXV:VM - Post by User

Comment by WarrantOfficeron Aug 22, 2022 7:53am
153 Views
Post# 34910674

RE:2 weeks to lift off

RE:2 weeks to lift offI too have become critical of managements ability to lead this company. The lack of transparency affects credibility. Well over a year after the formation of the Scientific Advisory Board and hiring of Dash Consulting, zero progress has been shared. Formula Development for the 5 Health Canada Approvals has taken much to long and with zero explaination. Zero news after the PP as to what the funds have been allocated for. FDA meeting was set for June 2022 after which regulatory submissions was supposed to happen, yet no news on this front. Management has over hyped and under performed. 

IMO, shareholders should be seriously concerned as management continously leaves share holders in the dark.
<< Previous
Bullboard Posts
Next >>